Relmada Therapeutics is Hammered on Top-line Results from Phase 3 RELIANCE III Trial Announcement

(24/7 MARKET NEWS) – Relmada Therapeutics, Inc. (Nasdaq: RLMD) is crashing after announcing Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder (“MDD”).

The late-stage biotechnology company addressing diseases of the central nervous system may be oversold and is at $5.69, down $26.00 (-82.04%), on volume of over 800 thousand shares traded in this morning’s premarket. Just because it may be oversold, doesn’t mean it can’t go lower, so tight stop losses and scaling into position strategies should be employed.

Its RELIANCE I and II trials of REL-1017, a potential new therapy for the adjunctive treatment of MDD, continue and its 52-week range is $15.735 to $38.68.

For full press release, please go to;–phase-3-reliance-iii-trial-for-rel-1017-as-a-monotherapy-for-the-treatment-of-major-depressive-disorder-301648190.html

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist